Novanta Inc

Research Novanta Inc (NOVT) on Bullrun: valuation model: 32.1% overvalued, market cap USD 5.62B, P/E 113.9. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerNOVT
• ExchangeNASDAQ
• CountryUnited States
• SectorTechnology
• IndustryScientific & Technical Instruments
• CurrencyUSD
• Valuation signal32.1% overvalued
• Market capUSD 5.62B
• P/E113.9
• Financial periodFY2025
• RevenueUSD 980.60M
• Revenue growth3.3%
• Net incomeUSD 53.83M
• Free cash flowUSD 48.43M
• Gross margin44.4%

Valuation Snapshot

Bullrun's latest valuation model marks Novanta Inc as 32.1% overvalued; latest market cap is USD 5.62B; P/E is 113.9.

About Novanta Inc

Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments.

Frequently asked questions

Is Novanta Inc overvalued or undervalued?

Bullrun's valuation model currently marks Novanta Inc as 32.1% overvalued.

What is Novanta Inc's market cap?

Novanta Inc's market capitalization is USD 5.62B.

What is Novanta Inc's P/E ratio?

Novanta Inc's price-to-earnings (P/E) ratio is 113.9.

What does Novanta Inc do?

Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally.